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TP53 mRNAThe tumor suppressor TP53 gene is one of the most frequently mutated in different types of human cancer.
Particularly in colorectal cancer (CRC), it is believed that TP53mutations play a role in the adenoma–carcino-
ma transition of tumors during pathological process. In order to analyze TP53 expressed alleles in CRC, we ex-
amined TP53 mRNA in tumor samples from 101 patients with sporadic CRC. Samples were divided in two
groups deﬁned according to whether they exhibit positive or negative P53 protein expression as detected
by immunohistochemistry (IHC). The presence of TP53 mutation was a common event in tumors with an
overall frequency of 54.5%. By direct sequencing, we report 42 different TP53 sequence changes in 55 CRC pa-
tients, being two of them validated polymorphisms. TP53 mutations were more frequent in positive than in
negative P53 detection group (pb0.0001), being the precise ﬁgures 79.6% and 30.8%, respectively. In addition,
the mutation proﬁles were also different between the two groups of samples; while most of the mutations
detected in P53 positive group were missense (38 out of 39), changes in P53 negative detection group include
7 insertions/deletions, 6 missense, 2 nonsense and 1 silent mutation. As previously observed, most mutations
were concentrated in regions encoding P53 DNA binding domain (DBD). Codons 175, 248 and 273 together
account for 36.7% of point mutations, in agreement with previous observations provided that these codons
are considered mutation hotspots. Interestingly, we detected two new deletions and two new insertions. In
addition, in three samples we detected two deletions and one insertion that could be explained as putative
splicing variants or splicing errors.
© 2012 Elsevier B.V.Open access under the Elsevier OA license. 1. Introduction
The tumor suppressor protein P53 is a transcription factor that
induces and/or represses the expression of target genes involved in
central pathways, such as control of the cell cycle and apoptosis,
among other pivotal functions (Joerger and Fersht, 2008; Soussi
and Wiman, 2007). Mutations in TP53 coding gene are found in ap-
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Soussi and Wiman, 2007), being the vast majority missense muta-
tions, preferentially localized in the DNA binding domain (DBD) of
P53 (Lamolle, et al., 2006; Petitjean, et al., 2007; Soussi and
Wiman, 2007). Such type of mutations could induce loss of protein
function by inactivating the binding property of P53 and thus, acting
as a possible cause of cell transformation (Kato, et al., 2003;
Petitjean, et al., 2007).
In normal cellular conditions, synthesis and degradation of P53 are
tightly regulated and the expression level is maintained very low.
Thus, in such conditions, P53 is generally not detectable by usual im-
munohistochemical techniques (Cooper and Haffajee, 1997; Levine,
et al., 1991; Renninson, et al., 1994).
Whereas other tumor suppressor genes, such as retinoblastoma or
APC (Adenomatous polyposis coli), are commonly inactivated by
frameshift or nonsense mutations (Olivier, et al., 2010; Vousden and
Lane, 2007), in the case of TP53, many cancers retain protein expres-
sion with only a single amino-acid change. These changes lead to both
the disruption of normal P53 function and the accumulation of mu-
tant P53 attaining levels that are high enough to be detected by rou-
tinary immunohistochemical techniques (Soussi and Lozano, 2005).
Many studies have indicated that the consequences of expressing
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P53. How these mutant P53 proteins exert this inﬂuence on tumor
spreading is being explored, and there is evidence that they can
alter P53 wild-type (wt) conformation, leading to protein stabiliza-
tion and accumulation in cells (Gannon, et al., 1990; Maslon and
Hupp, 2010).
Colorectal cancer (CRC) is the third cancer in terms of worldwide
incidence, and the second in terms of death from cancer, around
655,000 per year (http://www.who.int/en/). Speciﬁcally, in CRC, so-
matic mutations in TP53 gene are found in 43.3% of samples
(Petitjean, et al., 2007) (International Agency for Research on Cancer,
IARC TP53, R15 release, November 2010). A molecular model for
tumor progression has been well deﬁned in CRC. The progression
from adenoma to carcinoma is correlated with an accumulation of
speciﬁc genetic and epigenetic alterations, being TP53 gene a critical
player (Fearon, 2011; Fearon and Vogelstein, 1990).
The aim of this study was to determine the TP53mutation pattern
in CRC samples through complete mRNA coding region sequence
analysis in order to achieve a complete characterization of expressed
allele in a Brazilian population, and analyze the putative association
with protein accumulation. Samples were classiﬁed according to
their P53 expression status, positive or negative P53 protein expres-
sion as detected by immunohistochemistry (IHC). This approach
should contribute to the identiﬁcation of mutations associated with
P53 nuclear accumulation in CRC.
2. Materials and methods
2.1. Tumor samples
The samples analyzed in this study came from 101 patients with
sporadic colorectal tumors not treated with preoperative chemo ra-
diotherapy operated in the Hospital A.C. Camargo (São Paulo, Brazil).
Samples were divided into two groups, according to the expression
status of P53 as evaluated by immunohistochemistry (IHC) (Supple-
mentary Table 1). Fresh samples were matched with the formalin-
ﬁxed parafﬁn-embedded (FFPE) tissues of the same patients used
for IHC. The study was reviewed and approved by a duly constituted
ethics committee (1042/08).
2.2. Immunohistochemistry
IHC staining was performed on 3 μm-thick FFPE tumor sections
ﬁled from the same fresh sample studied. IHC studies were performed
using Horseradish Peroxidase (HRP) method, Advance HRP Link Poly-
mer Ampliﬁcation system (Dako, Glostrup, Denmark), and revealed
using 3,3′ diaminobenzidinetrahydrochloride, DAB (Dako, Glostrup,
Denmark).
Brieﬂy, tissues were deparafﬁnized using xylene and washed with
ethanol 100%. Then, sections were processed in 10 mM sodium citrate
buffer (pH 6.0) and heated for 40 min at 96 °C in pressure cooker for
antigen retrieval. Prior incubation with the primary antibody (Ab),
tissues were incubated 3 times for 5 min with 10% H2O2 in order to
block endogenous peroxidase, washed with deionized water, and
blocked with 100 μL of Protein Block Serum-Free (Dako, Glostrup,
Denmark) during 20 min. Sections were then incubated with 100 μL
of 1:100 dilution of a monoclonal Ab against P53 (clone DO-7, Dako,
Glostrup, Denmark) during 2 h in moist chamber at room tempera-
ture. 100 μL of Advance HRP Link (Dako, Glostrup, Denmark) was
used to amplify the signal and 100 μL of a 1:50 dilution of DAB was
used as a chromogen in a 5 min treatment. Tumoral cells showing a
clearly brown reaction in nuclei were classiﬁed as positive for P53 de-
tection. Less than 20% positive cells were established as cut-off to de-
ﬁne negative tumors. Based on these criteria, two groups containing
similar number of samples were generated, positive and negative
for P53 staining detection.2.3. RNA isolation
RNA was extracted from frozen tissues using a Trizol protocol and
a Precellys® (Bertin Technologies, Montigny le Bretonneux, France)
homogenizer. Brieﬂy, cells were lysed and homogenized during 10 s
at 6500 rpm in tubes containing magnetic beads and 1 mL of Trizol
per 50–100 mg of tissue. Then, lysates were transferred to a new
1.5 mL tube and incubated for 5 min a RT. After that, samples were
centrifuged at 12,000 g for 10 min at 4 °C. Finally, supernatants
were transferred to a 1.5 mL tube where a phenol-chloroform extrac-
tion was performed. The aqueous phase was recovered and the RNA
was precipitated with 1 volume of isopropanol and 20 μg of glycogen,
then washed with 70% ethanol and solubilised in RNAase-free water.
The concentration and quality of RNAwere evaluated using a Picochip
6000 on an Agilent 2100 Bioanalyzer (Agilent, Foster City, USA).
2.4. cDNA preparation, PCR ampliﬁcation and DNA sequencing
Reverse transcription reactions were performed on a Mastercycler
EppGradient (Eppendorf, Hamburg, Germany) in a ﬁnal volume of
20 μL using 1 μg of total RNA and the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, USA) according
to manufacturer's instructions.
1 μL of the unpuriﬁed cDNA product was used to amplify two
overlapping fragments of the entire TP53 coding region by PCR, the
5′ (nucleotides −54 to 654) and 3′ region (nucleotides 571 to
1215). The reaction mix containing 0.2 mM of each dNTP (Invitrogen,
Carlsbad, USA), 1.5 mMMgCl2, 0.3 μM of speciﬁc primers and 1.5 U of
Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, USA), was incu-
bated on Mastercycler EppGradient (Eppendorf, Hamburg, Germany)
as follows: 30 cycles at 95 °C for 1 min, 30 s at 52 °C for 5′ region
(E2ForE GACGGTGACACGCTTCCCTG and E6RevE CACCACCACAC-
TATGTCG) or 51 °C for 3′ region (E6ForE CCTCAGCATCTTATCCGAG
and E11RevE AGGCTGTCAGTGGGGAAC), and 2 min at 72 °C.
TP53 PCR products were puriﬁed using ExoSAP-IT (Exonuclease I
and recombinant Shrimp Alkaline Phosphatase) (USB, Cleveland,
USA). The DNA sequencing reaction was performed using BygDye
Terminator v3.1 Cycle Sequencing ready reaction kit (Applied Biosys-
tems, Foster City, USA). Both strands of PCR fragments were se-
quenced in order to obtain more reliable results. Sequencing
products were resolved in an ABI PRISM 3130xl Automated Genetic
Analyser (Applied Biosystems, Foster City, USA).
Sequencing results were analyzed and edited using BioEdit v7.0.9
and assembled using artemis v8. Products identities were conﬁrmed
by nucleotide blast at NCBI webpage, and detected mutations were
validated using mutation validation tools at IARC webpage (http://
www-p53.iarc.fr/MutationValidationCriteria.asp) (Petitjean, et al.,
2007).
2.5. Statistical analysis
Correlation between TP53 mutations and immunohistochemical
staining was assessed by two-tailed Fisher's exact test (GraphPad
Prism 5, Version 5.04, GraphPad Sofware Inc.). Values of Pb0.05
were considered statistically signiﬁcant.
3. Results
The purpose of this study was to analyze the complete coding re-
gion of TP53mRNA aiming to determine its mutation pattern in colo-
rectal cancer and the association with protein detection by IHC.
3.1. Alterations of P53 expression level
The concentration of P53 is normally very low, however in some
tumoral cells or tissues carrying a TP53 mutation, or mutations in
Table 1
TP53 mutations in CRC tissue samples.
Mutation
type
P53 positive P53 negative Total
n=49 n=52 n=101
Missense 38 6 44*
Nonsense 0 2 2
Frameshift 1 6 7
Silent 0 1 1
Others 0 1 1
Total 39 (79.6%) 16 (30.8%) 55**
Tissue samples from colorectal tumors exhibiting mutations in gene encoding P53
protein. The samples are discriminated according to the following criteria: pattern of
reaction with a P53 monoclonal antibody that indicates detectable levels of the
proteins (referred as positive or negative) and the type of mutation they exhibit.
Statistical association in two-tailed Fisher Exact Test are shown (* pb0.0001, **
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al., 1990), leading to detectable P53 levels (Levine, et al., 1991;
Renninson, et al., 1994; Steele and Lane, 2005). The accumulation of
P53 in selected tumoral sampleswas assessed by IHC using amonoclo-
nal Ab against P53, which recognizes an epitope located between the
N-terminal aminoacids 37 and 45 of the Transactivation Domain
(TAD) as described above. In negative tumors for P53 detection, as
well as in normal cells, P53 protein level is very low and as expected,
no signal was detected in the conditions used in this study (Fig. 1A).
Samples showing nuclear P53 signal in at least 20% of the cells were
classiﬁed as positive (Fig. 1B). Among the 101 tumor samples analyzed
in this work, 52 (51.5%) were negative for P53 detection, and 49
(48.5%) showed a strong signal for P53 in more than 20% of cells,
namely they were classiﬁed as positive.pb0.0001), where samples were grouped as follows: (*) Group 1: Samples bearing
missense mutation, Group 2: Samples bearing a mutation other than missense, Out-
come 1: positive for P53 IHC, Outcome 2: negative for P53 IHC; (**) Group 1: Samples
bearing a mutation, Group 2: Samples bearing no mutation, Outcome 1: positive for
P53 IHC, Outcome 2: negative for P53 IHC.3.2. TP53 mutations
TP53 sequence in CRC samples was analyzed. For this purpose,
total RNA was extracted, cDNA was synthesized and the complete
TP53 coding region was ampliﬁed as two overlapping fragments, se-
quenced and compared with the reference (wt) genomic TP53 se-
quence (GenBank accession number NC_000017). Among the 101
tumor samples analyzed in this study, 55 presented TP53 mutations
(54.5%) (Table 1, Supplementary Table 2).
In the P53 detection negative group, only 16 tumors (30.8%)
exhibited at least one TP53 alteration, being grouped according to
the type of mutation as follows: missense (n=6), insertions
(n=3), deletions (n=4), nonsense (n=2), synonymous (n=1).
Three insertions and three deletions led to frameshift, whereas the
other deletion did not produce any change in the open reading
frame (named as “other” in Table 1).
On the other hand, in the P53 positive detection group, 39 out of
49 (79.6%) tumors showed at least one mutation in the coding se-
quence of the protein. Among these, most were missense mutations
(38 out of 39), and one was a frame shift producing deletion
(Table 1).
These results clearly show that the frequency and proﬁle of TP53
mutations is different between P53 positive and negative detection
groups. The presence of mutations in TP53, in particular missense
mutations, is statistically associated with P53 accumulation in cells
(Fisher Exact test, pb0.0001). However, we could not detect any as-
sociation between TP53 mutations or P53 accumulation with clini-
cal data, such as advance or differentiation stage of tumors, sex,
ancestry, or external factors as smoking (Supplementary Table 1).Fig. 1. Immunohistochemical detection of P53 in negative (A) and positive (B) tumoral sam
tissues, there is no brown signal corresponding to precipitated DAB, while in positive tumor
0% of cells with positive signal, B: 90% of cells with positive signal. Midrange of P53 positivAnalyzing the study population as a whole, 42 different sequence
changes were detected, being 2 of them well described polymor-
phisms (see below) and the 40 remaining cancer related mutations
(Supplementary Table 2). Except for the missense substitutions, the
other mutation types were not seen in more than one sample. Of
these, two deletions (c.159del1, c.792_796del5) and two insertions
(c.672_673ins5, c.398-399ins4) were detected, to our knowledge,
for the ﬁrst time (Supplementary Table 3). Regarding missense muta-
tions we could identify 29 different events in 44 samples.
In our study 24 out of the 40 different mutations identiﬁed were
found only in P53 positive detection samples and correspond to 23
missense mutations in DNA binding domain and one frameshift pro-
ducing insertion. Of the 15 different mutations found exclusively in
P53 negative samples, 5 were missense mutations on DNA binding
domain, 6 correspond to insertions and deletions that produce frame-
shift, 2 nonsense changes; one located in the DNA binding domain
and another in the Tetramerization domain (TET), 1 deletion located
in the DNA binding domain but does not change the reading frame,
and 1 synonymous mutation located in the Tetramerization domain.
Finally, 1 missense mutation affecting DNA binding domain was
found in two P53 positive samples and in one P53 negative sample.
Related to the TP53 sequence taken as wt, two of the detected
changes are validated polymorphisms: 1) the c.108G>A
(Rs1800370) synonymous mutation detected in one sample, which
corresponds to a Proline coding codon, located in the Transactivationples using monoclonal antibody against P53. In negative samples, as well as in normal
al cells, the strong brown color indicates the presence of P53 in relatively high level. A:
e cells in positive samples: 71,6%.
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mal population (Petitjean, et al., 2007), and 2) the c.215C>G
(Rs1042522) substitution present in 82 samples, produces a change
from Proline to Arginine. This aminoacid altering substitution has an
average frequency of heterozygotes of 0.4923 in normal population
(Petitjean, et al., 2007). Polymorphisms were not considered for fur-
ther analysis.
3.3. Spatial distribution of TP53 mutations
The point mutations detected in this work were scattered over a
few codons; indeed out of the 393 codons that constitute this gene,
only 24 were affected by single base substitutions (polymorphisms
excluded). As in other human tumors (Holmila, et al., 2010;
Petitjean, et al., 2007; Rodrigues, et al., 1990; Walker, et al., 1994), co-
dons most frequently altered are located in the DNA binding domain
of TP53, 22 of 24 (91.7%), and 2 (8.3%) mutated codons localized out-
side this domain, are located at the Tetramerization Domain (Fig. 2).
Most mutations identiﬁed in this work were localized at nucleotide
sites commonly mutated in other human cancers (Petitjean, et al.,
2007). The only exception is c.1014C>T, that is synonymous and
was reported only once. Among these, the most frequently mutated
codons were 175, 248 and 273 (all three located in the DNA binding
domain of P53), which together comprise 36.7% of the point muta-
tions found (6, 7 and 5 mutations, respectively).
3.4. Mutation pattern
Analysis of the pattern of point mutations reported in this work
from the point of view of the wt and mutated nucleotide, showed
that C to T transitions were by far the most abundant, representingFig. 2. Spatial distribution of mutations along the TP53 coding gene. This ﬁgure shows the
protein domains are represented at the bottom in the colored box. TAD; Trans Activation D
Signal, TET; Tetramerization Domain, CT; Carboxi terminal Domain.49.0% of the changes, followed by the G→A transitions representing
26.5%. In turn, transversions were vastly less frequent with G→T
transversion with 6.1%, T→C and A→G transitions accounting for
4.1% each, and ﬁnally A→C, G→C, C→G, C→A and A→T each
representing 2.0% of the changes seen (Table 2). The scarcity of
G→T mutations is an interesting observation given that this type of
mutations are extremely frequent in other type of tumors, like lung
and liver (Hainaut and Pfeifer, 2001), and this has been associated
to the type of mutagenic agents to which the tissues or organs have
been exposed.3.5. Putative splicing variants
Two deletions and one insertion detected could be explained as
splicing variants. As seen in Fig. 3, the region deleted or inserted con-
tains sequences that could be used as alternative splicing sites. One
sample, contains in the 3′ end of the deleted region (ΔE55′,
c.376_396del21) AG bases which are the canonical 3′ splice site
(Hastings and Krainer, 2001; Tazi, et al., 2009). The same AG bases
are localized at the 3′ normal splice site in intron 4, and the surround-
ing nucleotides present in both the 5′ and 3′ splice sites correspond to
canonical sequences too, suggesting that errors in mRNA edition
could be a putative and interesting explanation. In this case, the 21
nucleotide deletion does not alter the reading frame of the protein,
producing a shorter P53 protein lacking 7 residues from the DNA
binding domain.
Likewise, the other deletion (ΔE53′, c.514_559del46) could be
considered as a modiﬁcation of splicing pattern since the bases locat-
ed at the 5′ end of the deleted region, GT, are the same as the normal
5′ splicing site from the intron 5. Once again, all surrounding se-
quences correspond to consensus bases for each region. This deletionnumber of point mutations affecting each codon. For functional reference the different
omain, PRR; Proline Rich Region, DBD; DNA Binding Domain, NLS; Nuclear Localization
Table 2
Mutation pattern.
Base change Total event number %
C>T 24 49.0
G>A 13 26.5
G>T 3 6.1
T>C 2 4.1
A>G 2 4.1
A>C 1 2.0
G>C 1 2.0
C>G 1 2.0
C>A 1 2.0
A>T 1 2.0
Total 49 100.0
Point mutations identiﬁed in this work discriminated according to the nucleotides
involved (wild type and mutated). It shows the number of times that a particular
nucleotide change was seen, including total nucleotide substitutions detected and
excluding polymorphisms.
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frame change.
In the same line, the insertion (IE63′, c.672_673ins5) contains in
the 5′ end the same GT bases that are located in the putative new 5′
splice site of the intron 6, suggesting that errors during edition
could be the cause of this change. Clearly, the 5 nucleotides insertion
alters the protein reading frame. This insertion was not detected in
previous studies.
It is important to note that none of these samples contain another
mutation in RNA sequence that could be related to splicing errors, for
example, by altering splicing enhancers sites located inside the exons
involved. This observation strongly suggests that particular splicing
modiﬁcations are associated with CRC.
4. Discussion
Here we report 40 different tumor suppressor gene TP53 muta-
tions in CRC from a Brazilian population. These mutations wereFig. 3. Schematic representation of deletions and insertion considered as possible splicing m
(ΔE55′ c.376_396del21, ΔE53′ c.514_559del46, and IE63′ c.672_673ins5) in each case. Regi
box, regions corresponding to introns are represented underlined and regions involved in m
represented both in exons and introns involved. AE55′: Deletion of 7 aminoacids from the 5
sertion of 5 nucleotides to the 3′ region of exon 6. E4, E5, E6 and E7: Exons 4, 5, 6, and 7, resp
between introns and exons in both wild type and mutant samples.found in 54.5% of samples analyzed, and such value agrees with the
average samples mutated in all human tumors (Guimaraes and
Hainaut, 2002; Joerger and Fersht, 2008; Petitjean, et al., 2007;
Soussi and Wiman, 2007). Particularly, the frequency of TP53 muta-
tions in colorectal cancer is approximately 40% to 50% (Iacopetta,
2003).
The majority of the TP53 mutations identiﬁed in this work
were missense, as it has been seen in previous studies in different
types of human cancers, such as hepatocellular carcinoma, epithe-
lial ovarian cancer, non-small cell lung cancer, sinonasal cancer
and esophageal squamous cell carcinomas, among others
(Audrezet, et al., 1993; Holmila, et al., 2010; Lee, et al., 2010;
Petitjean, et al., 2007; Renninson, et al., 1994; Rodrigues, et al.,
1990; Walker, et al., 1994).
We further analyzed the relationship between P53 expression
level and TP53 mutation pattern in tumoral cells. As unstressed cells
present low expression levels of P53 with a half-life of about
6–20 min (Filippini, et al., 1998; Harris and Levine, 2005; Steele and
Lane, 2005), P53 is not normally detected using conventional immu-
nohistochemical techniques (Cooper and Haffajee, 1997; Filippini, et
al., 1998; Harris and Levine, 2005; Levine, et al., 1991; Renninson, et
al., 1994). However, this pattern could be affected by mutations in
TP53 or in other related genes. Most TP53 mutations were located in
the DNA binding domain of the protein, and were associated with
an increase in protein accumulation which in turns leads to P53 de-
tection, as has been seen previously in primary lung cancer
(Gannon, et al., 1990; Steele and Lane, 2005). This feature is currently
used as a marker of P53 alterations in tumors (Iacopetta, 2003;
Rodrigues, et al., 1990; Walker, et al., 1994).
Previous studies have suggested that P53 accumulation is not a
general event in all types of CRC and that differences could be found
in tumors developed in speciﬁc locations, such as in rectum and
left-side colon (but not in right-side colon), indicating a different pat-
tern of tumor growth in relation to P53 status (Iacopetta, 2003;
Paluszkiewicz, et al., 2004). Thus, the observation of a positive signal
in cancer sections could depend on the tumor location as well as onistakes/variants in colorectal tumors. It shows normal (wt) and mutant splicing pattern
ons detected for each sample in our study are represented with normal letters inside a
utations are represented in italics. Sequences surrounding the putative splice sites are
′ end of exon 5. AE53′: Deletion of 12 aminoacids from the 3′ end of exon 5. IE63′: In-
ectively. I4, I5 and I6: Introns 4, 5 and 6, respectively. Arrows represent the boundaries
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proteins. In this work we analyzed samples that came from tumors
developed all over the colon and rectum, and they were treated as a
single group. In the P53 positive detection group, 79.6% of the sam-
ples carry a TP53 mutation, being the vast majority missense muta-
tions but also a frameshift producing insertion was observed. In
relation to the remaining samples from this group, namely those
that exhibit an altered P53 expression pattern but do not bear any
mutation in the TP53 gene, it is conceivable that other proteins that
regulate the P53 expression could be affected, such as HDM2,
HDM4, COP-1, PIRH-2, ARF, among others, leading to an increase in
P53 amount (Levine, et al., 2006).
On the other hand, only 30.8% of negative P53 samples had mu-
tations in TP53 coding sequence. This group contained 6 missense
changes, 6 frameshift alterations, 2 nonsense mutations and 1 syn-
onymous base substitution. In addition, 1 sample contained a dele-
tion that does not change the reading frame of the protein.
Needless to say, these mutations do not induce overexpression or
increased stability hence indicating that their mechanisms of action
could be substantially different. For the missense mutations, this re-
sult may reﬂect a speciﬁc effect of those particular mutations failing
to stabilize the protein, as was reported previously (Steele and
Lane, 2005). Deleted or truncated proteins resulting from nonsense
or frameshift mutations are usually not detectable by immunohisto-
chemical method because these proteins are very unstable in the
cell (Greenblatt, et al., 1994).
Between P53 positive and negative detection groups, this different
percentage of mutated samples was expected since TP53 mutations,
and in particular missense mutations, are tightly associated to protein
accumulation pattern in cancer (Renninson, et al., 1994).
Regarding spatial distribution of TP53 mutations, in this popula-
tion of CRC samples point mutations were mainly located at nucle-
otide sites commonly mutated in other human cancers. For
example, codons 175, 248 and 273, which are the most frequently
mutated codons in this population, are also frequently mutated in
most human tumors and are associated with loss of P53 function,
being a possible cause of cellular transformation (Kato, et al.,
2003; Petitjean, et al., 2007). Furthermore, we also detected point
mutations in another 19 codons located in the region encoding
the DNA binding domain of the protein, an observation that gives
further support to the generally accepted idea that loss of binding
ability of P53 to its DNA binding sites could be an important
event in the development of the disease.
Outside DNA binding domain, we detected two affected codons,
both located in the Tetramerization Domain, that could interfere
with the dimer and tetramer formation: the nonsense mutation
c.1045G>T due to the generation of truncated monomers unable to
establish properly contacts, while the silent mutation in this domain
(c.1014C>T) could affect the structure and dynamics of dimer stabili-
zation during protein translation, since both mechanisms occur at the
same time (Nicholls, et al., 2002). Then, these two codons could be
implicated, somehow, with the loss of P53 function in malignant mu-
tated cells.
We observed here that the most common base change was
C→T transitions, accounting for 49.0% of the nucleotides muta-
tions, followed by the G→A transition representing 26.5%. It has
been reported that among single-base substitutions in all type of
cancers, about 25% are C:G→T:A substitutions located at CpG
sites (Olivier, et al., 2010). It is worth reminding that the methyl-
ated cytosines at CpG dinucleotides mutate to Thymine at a rate
10 times higher than other nucleotides (Jones, et al., 1992).
About 3%–5% of cytosines in the human genome are methylated
at position 5′ by a postreplicative mechanism that is restricted to
CpG dinucleotides and is catalyzed by DNA methyltransferases.
The 5′methylcytosine (5mC) is less stable than cytosine and un-
dergoes spontaneous deamination into thymine at a rate ﬁvetimes higher than the unmethylated base. This process is enhanced
by oxygen and nitrogen radicals, leading to a higher load of CpG
transitions in cancers (Ambs, et al., 1999; Schmutte, et al., 1996;
Vaninetti, et al., 2008).
In addition, among the 22 CpG located in the P53 DNA-binding do-
main, three mutational hotspots (codons 175, 248, and 273) repre-
sent 60% of all CpG mutations in cancer, and another ﬁve residues
(196, 213, 245, 282, and 306) account for 26% of these mutations
(Olivier, et al., 2010) and at the same time most of them contain
CpG sites. Most of these sites were mutated in the Brazilian popula-
tion analyzed in this work, which is in agreement with these previous
observations.
Finally, it is important to note that we decided to analyze com-
plete mRNA coding region sequences in tumor samples, in order to
avoid possible detection biases that can arise due to the analysis of
only the gene segment that spans from exons 5 to 8. Although using
cDNA sequencing some frameshift mutations can be missed due to
Nonsense-Mediated Decay (NMD) that lead to RNA degradation
(Hentze and Kulozik, 1999), our approach allowed to assess a direct
and complete relationship between the P53 protein and its coding se-
quence. In addition, this strategy facilitated the detection of possible
splicing variants that might have been underestimated in previous
analyses.
Supplementary data to this article can be found online at doi:10.
1016/j.gene.2012.02.011.Acknowledgments
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